We are live on ! Find out more
FBIO icon

Fortress Biotech

49 hedge funds and large institutions have $18M invested in Fortress Biotech in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.17% less ownership

Funds ownership: 1.86%1.69% (-0.17%)

23% less funds holding

Funds holding: 6449 (-15)

30% less capital invested

Capital invested by funds: $25.8M → $18M (-$7.82M)

43% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 14

67% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 15

Holders
49
Holders Change
-15
Holders Change %
-23.44%
% of All Funds
0.79%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
8
Reduced
14
Closed
15
Calls
$60K
Puts
Net Calls
+$60K
Net Calls Change
-$27K

FBIO Hedge Fund Activity: Q4 2022 in Review

49 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q4 2022, worth a combined $18M — down 30% from $25.8M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of FBIO and 5 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 8 added.

The largest buyer was Jefferies Financial Group, opening a new position worth an estimated $3.17M. The largest seller was Tang Capital Management, exiting entirely with an estimated $3.61M sold.

  • 49 institutional investors held Fortress Biotech (FBIO) as of Q4 2022, down from 64 in Q3 2022.
  • Funds reported $18M of Fortress Biotech stock for Q4 2022, down 30% quarter-over-quarter.
  • 5 funds opened new Fortress Biotech positions in Q4 2022 and 15 closed out, a net change of -10 holders.
  • The largest Fortress Biotech buyer in Q4 2022 was Jefferies Financial Group, an estimated $3.17M added.
  • The largest Fortress Biotech seller in Q4 2022 was Tang Capital Management, an estimated $3.61M sold.

Based on aggregated 13F filings for Q4 2022.